Radius Health Inc (NASDAQ:RDUS)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday, May 5th. They presently have a $63.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 80.36% from the stock’s current price.
RDUS has been the topic of several other reports. Jefferies Group LLC dropped their target price on Radius Health from $40.00 to $34.00 and set a “hold” rating on the stock in a research report on Tuesday, May 2nd. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $65.00 target price on shares of Radius Health in a research report on Friday, April 28th. Canaccord Genuity reaffirmed a “buy” rating on shares of Radius Health in a research report on Friday, April 28th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Radius Health in a research report on Saturday, March 11th. Finally, Maxim Group set a $24.00 target price on Radius Health and gave the stock a “sell” rating in a research report on Saturday, March 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $56.83.
Radius Health (NASDAQ:RDUS) traded down 0.20% during mid-day trading on Friday, hitting $34.93. 798,738 shares of the stock traded hands. Radius Health has a 12-month low of $31.58 and a 12-month high of $59.88. The company has a 50 day moving average of $36.57 and a 200-day moving average of $41.96. The stock’s market cap is $1.52 billion.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.18) by $0.14. During the same quarter last year, the business earned ($0.94) earnings per share. Equities research analysts forecast that Radius Health will post ($4.41) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Radius Health Inc (RDUS) Stock Rating Reaffirmed by HC Wainwright” was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.themarketsdaily.com/2017/05/20/radius-health-inc-rdus-earns-buy-rating-from-hc-wainwright-updated.html.
In other news, major shareholder Growth N. V. Biotech bought 61,721 shares of the firm’s stock in a transaction that occurred on Wednesday, March 15th. The stock was acquired at an average price of $39.97 per share, with a total value of $2,466,988.37. Following the completion of the purchase, the insider now directly owns 4,415,930 shares of the company’s stock, valued at approximately $176,504,722.10. The acquisition was disclosed in a filing with the SEC, which is available at this link. Also, major shareholder Growth N. V. Biotech bought 35,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The shares were purchased at an average cost of $33.44 per share, with a total value of $1,170,400.00. Following the purchase, the insider now directly owns 4,890,799 shares of the company’s stock, valued at $163,548,318.56. The disclosure for this purchase can be found here. In the last three months, insiders bought 548,400 shares of company stock valued at $19,782,565. Company insiders own 16.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in RDUS. Sei Investments Co. boosted its position in shares of Radius Health by 17.8% in the third quarter. Sei Investments Co. now owns 2,082 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 314 shares in the last quarter. Ameritas Investment Partners Inc. purchased a new position in shares of Radius Health during the first quarter valued at $105,000. DIAM Co. Ltd. bought a new stake in shares of Radius Health during the third quarter valued at approximately $170,000. FNY Partners Fund LP bought a new stake in shares of Radius Health during the fourth quarter valued at approximately $160,000. Finally, Envestnet Asset Management Inc. increased its stake in shares of Radius Health by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 46 shares in the last quarter. 95.84% of the stock is owned by institutional investors and hedge funds.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, abaloparatide for subcutaneous injection, or abaloparatide-SC, has completed Phase III development for potential use in the treatment of women with postmenopausal osteoporosis.
Receive News & Ratings for Radius Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.